目的 观察石斛破壁草本联合奥美拉唑治疗慢性萎缩性胃炎的临床疗效。方法 回顾性选取2020年1月—2021年12月淮南朝阳医院收治的112例幽门螺杆菌阳性的慢性萎缩性胃炎患者，根据治疗方案不同分为对照组和试验组，每组各56例。对照组采用基础治疗方案（口服奥美拉唑肠溶胶囊、阿莫西林胶囊和克拉霉素缓释片）治疗；试验组在对照组基础上加用石斛破壁草本，冲泡服用，每次2袋，每天3次。两组患者治疗疗程均为1个月。采用世界卫生组织生活质量量表（WHOQOL-100）评估患者治疗前和治疗后的生活质量，采取酶联免疫吸附法（ELISA）检测两组患者治疗前后炎症因子C-反应蛋白（CRP）、白细胞介素-1β（IL-1β）、肿瘤坏死因子α（TNF-α）及血清胃蛋白酶原Ⅰ（PG I）、血清胃蛋白酶原Ⅱ（PGⅡ）和胃泌素-17（G17）水平。观察记录两组患者治疗总有效率及不良反应情况。结果 治疗前，两组患者WHOQOL-100评分比较，差异无统计学意义（P＞0.05）；治疗后，两组患者WHOQOL-100评分均显著高于治疗前（P＜0.01），治疗后试验组WHOQOL-100评分显著高于对照组（P＜0.01）。对照组和试验组总有效率分别为85.71%和96.42%，两组比较差异无统计学意义（P＞0.05）；试验组总显效率为78.57%，显著高于对照组的64.28%（P＜0.01）。治疗前，两组患者CRP、TNF-α和IL-1β水平比较差异无统计学意义（P＞0.05）；治疗后，两组患者CRP、TNF-α和IL-1β水平均较治疗前显著降低（P＜0.01），且治疗后试验组各炎性因子水平均低于对照组（P＜0.01）。治疗前，两组患者PGⅠ、PGⅡ和G17水平比较差异无统计学意义（P＞0.05）；治疗后两组患者PGⅡ和G17水平较治疗前显著降低（P＜0.01），PGⅠ水平较治疗前显著升高（P＜0.01）；治疗后，试验组PGⅡ和G17水平显著低于对照组（P＜0.05），PGⅠ水平显著高于对照组（P＜0.01）。治疗前两组患者中医证候评分比较差异无统计学意义（P＞0.05）；治疗后两组患者中医证候评分均较治疗前显著降低（P＜0.01），且治疗后试验组中医证候评分显著低于对照组（P＜0.05）。两组患者治疗过程中不良反应发生率无显著差异，且不良反应发生率较低。结论 西医常规治疗联合石斛破壁草本治疗慢性萎缩性胃炎临床效果显著，安全性好。

Objective To observe the clinical efficacy of breaking cell wall herb of Dendrobii Caulis combined with omeprazole in treatment of chronic atrophic gastritis. Methods A total of 112 patients with chronic atrophic gastritis and positive Helicobacter pylori treated in Huainan Chaoyang Hospital from January 2020—December 2021 were selected retrospectively. Patients were divided into control group and experimental group according to different treatment schemes, with 56 cases in each group. Patients in the control group were treated with basic treatment scheme (oral Omeprazole Enteric Coated Capsule, Amoxil Capsule and Clarithromycin Sustained-Release Tablets). On the basis of the control group, Patients in the experimental group were added breaking cell wall herb of Dendrobii Caulis, brewed and taken, two bags each time, three times a day. The treatment course of both groups was one month. The World Health Organization Quality of life scale (WHOQOL-100) was used to evaluate the quality of life of patients before and after treatment. The inflammatory factors C-reactive protein (CRP), interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA), and the levels of serum pepsinogen Ⅰ (PGⅠ), serum pepsinogen Ⅱ (PGⅡ) and gastrin-17 (G17) were detected by ELISA method. The total effective rate and adverse reactions of two groups were observed and recorded. Results Before treatment, there was no significant difference in WHOQOL-100 score between two groups (P>0.05). After treatment, the WHOQOL-100 score of two groups was significantly higher than that before treatment (P<0.01). Compared with the control group, the WHOQOL-100 score of the experimental group was significantly higher than that of the control group (P<0.01). The total effective rates of the control group and the experimental group were 85.71% and 96.42% respectively. There was no significant difference between two groups (P>0.05). The total effective rate of the experimental group was 78.57%, which was significantly higher than 64.28% of the control group (P<0.01). Before treatment, there was no significant difference in level of CRP, TNF-α and IL-1β in two groups (P>0.05). After treatment, the levels of CRP, TNF-α and IL-1β in two groups were significantly lower than those before treatment (P<0.01), and the levels of inflammatory factors in the experimental group were lower than those in the control group (P<0.01). Before treatment, there was no significant difference in the levels of PGⅠ, PGⅡ and G17 between two groups (P>0.05). After treatment, the levels of PGⅡ and G17 in two groups were significantly lower than those before treatment (P<0.01), and the level of PGⅠ was significantly higher than that before treatment (P<0.01). After treatment, the levels of PGⅡ and G17 in the experimental group were significantly lower than those in the control group (P<0.05), and the level of PGⅠ was significantly higher than those in the control group (P<0.01). There was no significant difference in TCM syndrome scores between two groups before treatment (P>0.05). After treatment, the TCM syndrome scores of two groups were significantly lower than those before treatment (P<0.01), and the TCM syndrome scores of the experimental group were significantly lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups, and the incidence of adverse reactions was low. Conclusion Breaking cell wall herb of Dendrobii Caulis combined with the conventional treatment of Western medicine is effective and safe in treatment of chronic atrophic gastritis.

R975